Current Perspectives, Challenges and Advances in Cell Based Therapies
Cell-based immunotherapy is based on the seemingly simple principle of harnessing the power of the immune system to combat cancer, and is emerging as an important clinical tool. The remarkable success of CAR-T cell therapies demonstrate that cell based therapies are effective at eradicating hematolo...
Saved in:
HerausgeberIn: | |
---|---|
Sonstige: | |
Year of Publication: | 2020 |
Language: | English |
Physical Description: | 1 electronic resource (192 p.) |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
993545832404498 |
---|---|
ctrlnum |
(CKB)5400000000045193 (oapen)https://directory.doabooks.org/handle/20.500.12854/73716 (EXLCZ)995400000000045193 |
collection |
bib_alma |
record_format |
marc |
spelling |
Trikha, Prashant edt Current Perspectives, Challenges and Advances in Cell Based Therapies Frontiers Media SA 2020 1 electronic resource (192 p.) text txt rdacontent computer c rdamedia online resource cr rdacarrier Cell-based immunotherapy is based on the seemingly simple principle of harnessing the power of the immune system to combat cancer, and is emerging as an important clinical tool. The remarkable success of CAR-T cell therapies demonstrate that cell based therapies are effective at eradicating hematological malignancies, and therefore hold great promise for other cancers. However, there are number of challenges that limit the full potential of cell based therapies, especially for solid cancers. T cells and NK cells represent major lymphocyte populations that are involved in immune surveillance and tumor eradication, and both are emerging as important players for cell based immunotherapy. Although they use different mechanisms for recognizing cancer cells, they complement each other during tumor eradication. NK cells have many functional similarities to T cells and represent the closest innate immune cell lineage to adaptive immune cell populations. Transcriptome analysis has also revealed similar phylogenetic origin of the two lymphocyte populations. The hurdles that impact therapeutic success of these cells include trafficking of lymphocytes to the tumor sites, recognition of solid tumors, and overcoming the inhospitable tumor microenvironment (TME) including the presence of suppressive cells (Treg and MDSC) and immune suppressive cytokines (TGFβ). The full potential of cell based therapies may be realized once tools to overcome these barriers are developed. This Research Topic collects articles critically examining these obstacles and the novel strategies being developed for cell-based therapies to overcome them. English Medicine bicssc Oncology bicssc immunotherapy NK cell tumor micoenvironment CAR (chimeric antigen receptor) T cells cell based therapy 2-88963-564-3 Thakar, Monica edt Russell Cruz, Conrad edt Trikha, Prashant oth Thakar, Monica oth Russell Cruz, Conrad oth |
language |
English |
format |
eBook |
author2 |
Thakar, Monica Russell Cruz, Conrad Trikha, Prashant Thakar, Monica Russell Cruz, Conrad |
author_facet |
Thakar, Monica Russell Cruz, Conrad Trikha, Prashant Thakar, Monica Russell Cruz, Conrad |
author2_variant |
p t pt m t mt c c r cc ccr |
author2_role |
HerausgeberIn HerausgeberIn Sonstige Sonstige Sonstige |
title |
Current Perspectives, Challenges and Advances in Cell Based Therapies |
spellingShingle |
Current Perspectives, Challenges and Advances in Cell Based Therapies |
title_full |
Current Perspectives, Challenges and Advances in Cell Based Therapies |
title_fullStr |
Current Perspectives, Challenges and Advances in Cell Based Therapies |
title_full_unstemmed |
Current Perspectives, Challenges and Advances in Cell Based Therapies |
title_auth |
Current Perspectives, Challenges and Advances in Cell Based Therapies |
title_new |
Current Perspectives, Challenges and Advances in Cell Based Therapies |
title_sort |
current perspectives, challenges and advances in cell based therapies |
publisher |
Frontiers Media SA |
publishDate |
2020 |
physical |
1 electronic resource (192 p.) |
isbn |
2-88963-564-3 |
illustrated |
Not Illustrated |
work_keys_str_mv |
AT trikhaprashant currentperspectiveschallengesandadvancesincellbasedtherapies AT thakarmonica currentperspectiveschallengesandadvancesincellbasedtherapies AT russellcruzconrad currentperspectiveschallengesandadvancesincellbasedtherapies |
status_str |
n |
ids_txt_mv |
(CKB)5400000000045193 (oapen)https://directory.doabooks.org/handle/20.500.12854/73716 (EXLCZ)995400000000045193 |
carrierType_str_mv |
cr |
is_hierarchy_title |
Current Perspectives, Challenges and Advances in Cell Based Therapies |
author2_original_writing_str_mv |
noLinkedField noLinkedField noLinkedField noLinkedField noLinkedField |
_version_ |
1796651970652536832 |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>02852nam-a2200397z--4500</leader><controlfield tag="001">993545832404498</controlfield><controlfield tag="005">20231214133045.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr|mn|---annan</controlfield><controlfield tag="008">202111s2020 xx |||||o ||| 0|eng d</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(CKB)5400000000045193</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(oapen)https://directory.doabooks.org/handle/20.500.12854/73716</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(EXLCZ)995400000000045193</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Trikha, Prashant</subfield><subfield code="4">edt</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Current Perspectives, Challenges and Advances in Cell Based Therapies</subfield></datafield><datafield tag="260" ind1=" " ind2=" "><subfield code="b">Frontiers Media SA</subfield><subfield code="c">2020</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 electronic resource (192 p.)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Cell-based immunotherapy is based on the seemingly simple principle of harnessing the power of the immune system to combat cancer, and is emerging as an important clinical tool. The remarkable success of CAR-T cell therapies demonstrate that cell based therapies are effective at eradicating hematological malignancies, and therefore hold great promise for other cancers. However, there are number of challenges that limit the full potential of cell based therapies, especially for solid cancers. T cells and NK cells represent major lymphocyte populations that are involved in immune surveillance and tumor eradication, and both are emerging as important players for cell based immunotherapy. Although they use different mechanisms for recognizing cancer cells, they complement each other during tumor eradication. NK cells have many functional similarities to T cells and represent the closest innate immune cell lineage to adaptive immune cell populations. Transcriptome analysis has also revealed similar phylogenetic origin of the two lymphocyte populations. The hurdles that impact therapeutic success of these cells include trafficking of lymphocytes to the tumor sites, recognition of solid tumors, and overcoming the inhospitable tumor microenvironment (TME) including the presence of suppressive cells (Treg and MDSC) and immune suppressive cytokines (TGFβ). The full potential of cell based therapies may be realized once tools to overcome these barriers are developed. This Research Topic collects articles critically examining these obstacles and the novel strategies being developed for cell-based therapies to overcome them.</subfield></datafield><datafield tag="546" ind1=" " ind2=" "><subfield code="a">English</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Medicine</subfield><subfield code="2">bicssc</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Oncology</subfield><subfield code="2">bicssc</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">immunotherapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">NK cell</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">tumor micoenvironment</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">CAR (chimeric antigen receptor) T cells</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cell based therapy</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">2-88963-564-3</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Thakar, Monica</subfield><subfield code="4">edt</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Russell Cruz, Conrad</subfield><subfield code="4">edt</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Trikha, Prashant</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Thakar, Monica</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Russell Cruz, Conrad</subfield><subfield code="4">oth</subfield></datafield><datafield tag="906" ind1=" " ind2=" "><subfield code="a">BOOK</subfield></datafield><datafield tag="ADM" ind1=" " ind2=" "><subfield code="b">2023-12-15 05:41:07 Europe/Vienna</subfield><subfield code="f">system</subfield><subfield code="c">marc21</subfield><subfield code="a">2022-04-04 09:22:53 Europe/Vienna</subfield><subfield code="g">false</subfield></datafield><datafield tag="AVE" ind1=" " ind2=" "><subfield code="i">DOAB Directory of Open Access Books</subfield><subfield code="P">DOAB Directory of Open Access Books</subfield><subfield code="x">https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5338102240004498&Force_direct=true</subfield><subfield code="Z">5338102240004498</subfield><subfield code="b">Available</subfield><subfield code="8">5338102240004498</subfield></datafield></record></collection> |